Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil initially worked but then failed. Trinov has significantly reduced shedding and shows promising results.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

The user has been using 1mg Finasteride daily for six months, experiencing reduced shedding and itchiness but some frontal thinning. They are considering adding Minoxidil and have started dermarolling to enhance results.

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

A user discusses using a serum called Dallixa, containing minoxidil-like and bimatoprost-like compounds, for hair loss and greying. The user's dermatologist advised against finasteride and suggested the serum might improve hair pigmentation.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

Switching from ketoconazole to a ciclopirox and zinc pyrithione shampoo significantly reduced hair fall. The user is considering whether to continue using ketoconazole occasionally or combine both shampoos weekly.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

A user shared an 8.5-month update on their hair transplant of 1064 grafts done by Dr. Kaan Pekiner in Ankara, Turkey, costing $3500. They are also using finasteride 2.25 mg weekly and have reduced shampoo use.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The user has been using topical finasteride and minoxidil for a month to address hair thinning. They are experiencing shedding but have noticed small hairs on their temples.

The user is experiencing progress in hair growth using 0.5mg Finasteride, 5mg Minoxidil, and 1mg Biotin daily but is also developing gynecomastia. They plan to continue the treatment for six months unless the side effects worsen.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

A user expressed disappointment that their hair loss worsened after 11 months using topical finasteride with TrichoSol, despite no side effects and initial signs of improvement. They asked for advice and opinions on their treatment and alternatives, with suggestions including switching to oral finasteride or dutasteride, starting minoxidil, and addressing their seborrheic dermatitis with different shampoos or medical advice.

Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.

The user applied half a can of Minoxidil foam and is worried about potential side effects. They are feeling paranoid and unable to sleep.

User shares 8-month hair growth progress using 2.5mg oral minoxidil and 2ml topical minoxidil/finasteride mix. Others comment on noticeable improvement and discuss user's journey and treatment details.

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

, I’m on fin as well. This conversation discussed the user's successful results from 5 weeks of taking an oral minoxidil medication and their experience with hair shedding while using it in combination with finasteride.

The user discusses using compounded oral minoxidil due to the ineffectiveness and inconvenience of topical minoxidil for diffuse thinning. They question the efficacy of compounded minoxidil compared to original tablet forms and express concerns about the importance of excipients and binders.

The acne medication Winlevi, which contains Clascoterone, is available in the U.S. and may slow down hair loss until a higher concentration treatment, Breezula, is released.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

A 15% discount is offered on hair research products like RU58841 and TEMPOL at Chemyo.com. The legality of selling these compounds is confirmed by the seller.

The conversation discusses hair loss treatments, specifically using Minoxidil, finasteride, and RU58841. The focus is on progress observed at the temples after one month of treatment.

The user is experiencing worsening hair loss despite undergoing monthly injectable finasteride, clay masks, laser therapy, and microneedling. They are concerned about severe shedding in areas not typically affected by male pattern baldness and are considering seeking a second opinion.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. L'Oreal's study on Stemoxydine 5% claims a 4% increase in hair density after 3 months, but some users question potential bias.